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Abstract
Introduction. The aim of this study was to report our preliminary results regarding the use of the reposition-
able self-expanding nitinol stent in a cohort of patients with femoro-popliteal artery occlusion/stenosis.
Material and methods. The study groups consisted a total of 8 patients (10 extremities) between 47 and 
70 years of age who presented with typical symptoms of intermittent claudication and/or critical limb ischaemia 
(Fontaine stage II–IV) and underwent primary elective superficial femoral artery percutaneous transluminal an-
gioplasty and/or stenting using a Jaguar repositionable self-expanding nitinol stent in the dates of 2013–2015. 
Information for patency at 6th month after the stenting procedure was obtained.
Results. The mean operation time was 38.56 ± 26.40 minutes. No patients had procedure-related stent 
fracture, distal thromboembolism, haematoma, femoral pseudoaneurysm or stent occlusion. At 6-month follow-
-up, at least one categorical improvement was observed in 7 patients (87.5% of intent-to-treat population).
Conclusions. The Jaguar self-expanding nitinol stent has several technical advantages, and its use was 
associated with a low risk of complications. Further study is warranted to establish its superiority in providing 
good long-term patency. 
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Introduction
Lower extremity peripheral artery disease (PAD) 
is a major health problem leading to significant mor-
bidity and even mortality. As a result of the evolving 
knowledge regarding the multi-systemic nature of 
atherosclerotic disease, PAD is no longer considered 
to be a problem limited to the extremity involved, but 
has increasingly been recognized as a distinct entity re-
quiring a multifaceted approach including interventional 
treatment [1]. As the disease course may be asympto-
matic until stenosis reaches an advanced stage, PAD 
is commonly underdiagnosed and undertreated [2]. 
In the last decade, the total number of PAD cases 
was reported to have increased by 13.1% to 28.7% 
worldwide, with the most marked increases in preva-
lence observed among patients with advanced disease 
and those living in low-income countries [3]. Although 
recent advances in diagnostic modalities and increasing 
use of endovascular techniques have led to a significant 
decrease in amputation rates, mortality has remained 
unchanged in patients hospitalized for PAD [4].
Patients with superficial femoral artery stenosis 
make up an important proportion of patients with 
PAD, and since this type of involvement was reported 
to be most commonly associated with intermittent 
claudication, this patient population has been subject 
to intensive research on methods to prevent disease 
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progression and further complications [5]. Although 
endovascular revascularization is the recommended 
and preferred treatment in patients with single su-
perficial femoral artery stenosis shorter than 10 cm 
or single occlusion shorter than 5 cm Trans-Atlantic 
Inter-Society Consensus [TASC] A or in those having 
multiple stenosed or occluded segments shorter than 
5 cm (TASC type B), whether primary stenting achieves 
better outcomes than primary transluminal angioplasty 
in patients with superficial femoral artery (SFA) lesions 
has remained controversial [6, 7].
Recently, there has been an increasing trend towards 
the initial use of endovascular stents in the treatment of 
SFA lesions. However, despite their suggested technical 
advantages, balloon expandable stainless steel stents 
did not demonstrate a superior sustained benefit over 
percutaneous transluminal angioplasty. This outcome 
has led to the development of second-generation, 
self-expanding nitinol stents that are more flexible and 
thus more resistant [8]. The Jaguar SM stent (Balton, 
Warsaw, Poland) is a novel self-expanding nitinol stent 
featuring a unique deployment system that allows 
correction of the stent position even after the partial 
release of the stent inside the arterial lumen. A recent 
study that evaluated its usefulness in patients with iliac 
artery disease reported promising results [9]. However, 
to our knowledge, there has been no study reporting 
the use of the Jaguar stent for the treatment of super-
ficial femoral artery lesions. 
Here we report our preliminary results regarding 
the use of the Jaguar self-expanding stent in a cohort 
of patients with TASC type A-C stenosis.
Material and methods
The study was approved by the local ethics com-
mittee. All patients were informed about the planned 
procedure and provided informed consent. This retro-
spective cohort study was undertaken in two tertiary 
hospitals and a total of 39 patients (mean age 63.42 ± 
9.23 years) undergoing endovascular peripheral arterial 
interventions for PAD between the dates of 2013–2015. 
A total of 8 patients (10 extremities) between 47 and 
70 years of age (mean age 59.40 ± 7.32 years) who 
presented with typical symptoms of intermittent clau-
dication and/or critical limb ischaemia (Fontaine stage 
II–IV) and underwent primary elective SFA percutane-
ous transluminal angioplasty (PTA) and stenting using 
a Jaguar repositionable self-expanding nitinol stent in 
the dates of 2013–2015 were considered eligible for 
the study. 
All patients were initially evaluated with duplex 
ultrasound scanning, and those with positive findings 
indicating diminished arterial flow to the lower extrem-
ity underwent computed tomography (CT) angiography 
to reveal the degree and extent of the stenosis.
Patients were considered eligible if they had TASC 
type A (single stenosis < 10 cm in length or single 
occlusion < 5 cm in length) or TASC type B (multiple 
lesions < 5 cm or single stenosis < 15 cm not involving 
the popliteal artery) or TASC type C (multiple stenosis 
or occlusions totalling > 15 cm with or without heavy 
calcification) superficial femoral artery lesions [6]. Pa-
tients were excluded if they had unilateral or bilateral 
aorto-iliac stenosis or occlusion, chronic total occlusion 
in the common or superficial femoral artery (> 20 cm 
involving the popliteal artery) or popliteal artery or 
underwent to primary elective PTA only. Patients with 
diffuse peripheral arterial involvement and those with 
a clear indication for concomitant or staged vascular 
procedures were also excluded. Patients with unstable 
coronary symptoms and those with a high risk profile for 
coronary artery disease were not included, and instead 
referred for cardiovascular investigation, whereas asymp-
tomatic patients with a low risk profile for coronary 
artery disease did not undergo coronary angiography. 
Patient demographics, counselling charts, and labora-
tory findings were recorded. Pre-procedural CT angiog-
raphy evaluation was performed by a radiologist who was 
unaware of patients. All of the patients had PAD. Smoker 
patients were encouraged to undertake smoking cessation 
and patients who had high LDL levels (> 100 mg/dL) were 
initiated on statins. Hypertensive patients were treated 
appropriately and diabetic patients underwent consulta-
tion with an endocrine and diabetes specialist to control 
blood sugar levels before the procedure. Patients who had 
a previous history of coronary artery disease underwent 
consultation with a cardiologist for necessity of coronary 
angiography before the procedure.
Procedure
In all patients, acetylsalicylic acid 100 mg/day and 
clopidogrel 75 mg/day were initiated on the same day 
of the procedure. All procedures were performed in a 
vascular surgery operating room under local anaesthesia 
and with the aid of fluoroscopy guidance using a porta-
ble X-ray machine. All procedures were performed by 
the same vascular surgeons.
With the patient in a supine position, skin antisepsis 
was performed with povidone iodine, followed by the 
placement of sterile surgical drapes. A 5–6 Fr intro-
ducer catheter was placed in the ipsilateral common 
femoral artery and advanced from the groin distally in 
a downward direction. Intra-arterial injection of 5000 IU 
heparin was followed by preliminary angiography 
to reveal the stenosis. The procedure proceeded in 
a percutaneous fashion, according to the manufacturer’s 
instructions.
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A guidewire was inserted through the introducer 
catheter using either a subintimal angioplasty or intra-
luminal angioplasty technique. During the subintimal 
technique, predilatation was performed after re-entry 
to the intraluminal space was achieved. A self-ex-
panding nitinol stent delivery sheath was introduced 
over the guidewire and advanced beyond the distal 
end of the lesion. The stent position was checked 
fluoroscopically, and the system allowed for accurate 
stent placement before deployment by re-positioning 
in the upward and downward direction based on serial 
fluoroscopic images. Finally, the stent was released, 
and the delivery system was removed. Post-dilatation 
was performed when necessary. The introducer was 
removed, and the bleeding was controlled by manual 
compression (Fig. 1). 
After the procedure, patients were transferred 
to the vascular surgery ward and discharged on the 
following day. Distal pulses were examined before the 
discharge, and the patients were invited to a follow-up 
examination 6 months after the procedure. Follow up 
included clinical assessment and physical examination 
of the patient. Doppler ultrasound imaging was per-
formed to check for stent patency if the patients were 
symptomatic or distal lower extremity pulses were 
weak or absent.
Statistical analysis
Statistical analyses were performed using MedCalc 
statistical software. Normal distribution of the param-
eters was assessed using visual histograms and the 
Shapiro-Wilk test. Continuous parameters were ex-
pressed as mean ± standard deviation, and categorical 
parameters as numbers and percentages within brack-
ets. A p value less than 0.05 was considered statistically 
significant. 
Figure 1. Representative fluoroscopic images during peripheral artery stenting; A. Guidewire advanced beyond the lesion within 
the superficial femoral artery; B. Predilatation; C. Stent deployed; D. Post-procedural view
A B
C D
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Table 1. Baseline characteristics of intent-to-treat patients 
(N = 8)
Variable Mean ± SD or N (%)
Age (years) 59.40 ± 7.32
Males 8 (100%)
Clinical presentation
Fontaine IIb 5 (62.5%)
Fontaine III 2 (25.0%)
Fontaine IV 1 (12.5%)
Diabetes 5 (62.5%)
Smoking 7 (87.5%)
Hypertension 5 (62.5%)
Dyslipidaemia 4 (50.0%)
Stable coronary artery disease 4 (50.0%)
Table 2. Distribution of TASC II lesional involvement in intent-
-to-treat extremities (N = 10) 
N (%)
Type A lesions 7 (70.0%)
Type B lesions 2 (20.0%)
Type C lesions 1 (10.0%)
Total 10
Results
The age of the study subjects was between 47 and 
70 years of age (mean age 59.40 ± 7.32years) and all 
were males. Five patients (62.5%) patients (7 extremi-
ties) had severe claudication (< 200 m walking distance, 
Fontaine stage IIb). Critical limb ischaemia, defined as 
the presence of ischaemic rest pain (Fontaine stage III) 
or ulcers or gangrene (Fontaine stage IV) lasting for 
more than 2 weeks, was present in 3 patients (37.5%). 
Mean lesion length was 4.3 ± 3.22 cm and eight (80%) 
of the lesions were stenoses. Baseline patient charac-
teristics are shown in Table 1 and the distribution of 
TASC II lesional involvement in patients’ extremities is 
included in Table 2.
Mean operation time was 38.56 ± 26.40 minutes, and 
mean amount of contrast used was 50.36 ± 27.17 mL 
during the procedure. Unilateral stenting was performed 
in 6 patients, and bilateral stenting was performed in 
2 patients. Thus, there were a total of 8 intent-to-treat 
patients and 10 intent-to-treat extremities. The proce-
dural information regarding intent-to-treat extremities 
is included in Table 3. The procedure was successfully 
completed in all patients, and no patients required any 
additional intervention or conversion to open surgery. 
Table 3. Procedural information regarding intent-to-treat 
extremities (N = 10)
Variable N
Technique
Stenting via subintimal angio-
plasty
2
Stenting via intraluminal angio-
plasty
8
Location
SFA stenting 6
Popliteal artery stenting 2
Both SFA and popliteal artery 
stenting
2
SFA — superficial femoral artery
During the procedure, repositioning of the stent was 
performed in 2 (20.0%) extremities to avoid occluding 
large collateral side-branches originating quite close to 
the proximal or distal end of the stenotic lesion. 
None of the patients had procedure-related com-
plications and complications on follow-up like stent 
fracture, distal thromboembolism, haematoma, fem-
oral pseudoaneurysm, or early stent occlusion. One 
patient who initially had Fontaine IV symptoms and 
type C stenosis and underwent unilateral stenting was 
re-hospitalized with acute worsening of lower extrem-
ity ischaemic symptoms 1 month after the procedure. 
CT angiography revealed 95% in-stent stenosis, and 
this patient underwent a surgery.
All remaining patients completed 6-month fol-
low-up. Clinical assessment revealed that 4 of 5 pa-
tients with Fontaine stage IIb PAD shifted to Fontaine 
stage IIa, one of 5 patients with Fontaine stage IIb 
PAD shifted to Fontaine stage I, and all 2 patients with 
Fontaine stage III PAD shifted to Fontaine stage IIb. 
One patient with Fontaine stage IV PAD did not com-
plete 6-month follow-up as described above. Thus, at 
least one categorical improvement was observed in 
9 extremities (90.0% of the intent-to-treat population). 
In the follow-up period, the superficial femoral artery 
stent was patent in all per-protocol extremities (90.0% 
of intent-to-treat extremities). 
Discussion 
In this preliminary study, we achieved satisfactory 
outcomes using the Jaguar repositionable self-expanding 
nitinol stent for the treatment of superficial femoral 
artery stenosis or occlusions. The technique provided 
excellent post-procedural outcomes and had a low rate 
of complications. Also, given the acceptable operative 
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times we obtained, it offers a steep learning curve for 
the operator through its easy implantation technique. 
The delivery system of the device is flexible and allows 
for advancing through tortuous arterial segments, al-
though this feature was not of apparent use to us during 
our practice since the superficial femoral artery follows 
a straighter course within the thigh when compared 
to the aorto-iliac system. Nevertheless, none of our 
patients had stent-related mechanical complications 
such as fracture or displacement, which is attributable 
to the basic feature of the stent itself being made of 
a single nitinol wire without welds and solders, thus 
providing further elasticity. 
Currently, endovascular therapy is the treatment of 
choice in patients with single short segment stenosis or 
occlusion (type A lesions), and it is also recommended 
in the presence of multiple short-segment stenoses 
(type B lesions) [6]. However, whether implantation 
of stents provides better outcomes when compared 
with PTA alone is still controversial [10]. Several studies 
have compared stents with various treatment options. 
In an earlier meta-analysis, Balk and colleagues [11] 
found no significant difference in clinical outcomes 
including re-intervention, amputation, mortality, and 
complication rates between patients receiving either 
PTA or stenting. In a randomized trial, Kedora et al. [12] 
compared Viabahn stent grafting and bypass surgery for 
the treatment of SFA occlusion. Similar to our study, 
their patients had an adequate distal vascular bed and 
were also free of aorto-iliac occlusive disease. Clinical 
improvement, limb salvage and mortality did not differ 
at the end of follow-up.
Nevertheless, recent data has indicated more 
promising results regarding the effectiveness of ad-
ditional techniques in the treatment of infrainguinal 
peripheral artery disease. In a recent meta-analysis 
including a total 40 randomized trials, Simpson et al. [13] 
sought to determine whether patients undergoing 
endovascular treatment for femoro-popliteal artery 
stenosis/occlusion benefited from additional tech-
niques including self-expanding stents, drug-coated 
balloons, and drug-eluting stents. The authors report-
ed that self-expanding stents were associated with 
a lower restenosis rate at 6 months and also that stent 
grafting significantly reduced restenosis compared to 
percutaneous transluminal angioplasty alone. A more 
recent meta-analysis revealed that nitinol stents were 
associated with superior technical success, whereas 
drug-eluting stents provided better long-term patency 
in femoro-popliteal artery lesions [14]. Our preliminary 
experiences with the self-expanding Jaguar nitinol stent 
support the technical superiority of nitinol stenting; the 
procedure was quite simple in that we were able to 
perform it without C-arm fluoroscopy but rather with 
the aid of a portable X-ray machine. The procedure 
was performed in a vascular surgery operating room 
since a hybrid revascularization room has not yet been 
established in our institution.
Primary nitinol stenting is preferable for the treat-
ment of femoro-popliteal artery occlusive disease, 
despite conflicting results regarding its long-term 
benefit [15, 16]. In biomechanical studies, stents in the 
femoro-popliteal artery were shown to be subject to 
compression and bending by articular movement, which 
was postulated to lead to stent failure in the long term [17]. 
Moreover, bare nitinol stenting was shown to be as-
sociated with high rates of restenosis. These findings 
have led to the development of numerous new stents 
to increase graft patency survival [18, 19]. Among them, 
the Supera helical interwoven stent stands out for its 
enhanced flexibility to resist against fracture when 
placed in the femoro-popliteal artery. Early experience 
using this type of stent was promising, with primary 
patency rates of 83.5% and 78.6% at 6- and 12-month 
follow-up, respectively [20]. The technical features of 
this stent are similar to that used in the present study. 
Given that none of the patients in this previous cohort, 
similar to ours, had stent fractures during follow-up, 
newer stents seem to provide more promising long-
term outcomes compared to those used in the past.
Our preliminary study had several limitations includ-
ing a non-randomized design, lack of control group and 
low number of patients. At follow up, Doppler ultra-
sonography was only done when patients had symptoms 
or when physical examination revealed poor distal flow. 
Angiographic evaluation was performed only in those 
patients having signs suggestive of stent occlusion in 
Doppler assessment. Thus, follow up data lacked ob-
jective imaging data to draw a conclusion regarding the 
patency rate of the stent used in this study and also its 
influence on disease progression.
Conclusions
Currently there is no ongoing international study 
registered in clinicaltrials.gov regarding the use of 
self-expanding Jaguar nitinol stents. Our preliminary 
study concluded that this newer stent has several 
technical advantages, and its use was also associated 
with a low risk of complications. Further study is 
warranted to establish its superiority in providing 
good long-term patency, as has been proposed based 
on its enhanced flexibility and resistance against 
bending forces.
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